Novel Biologics for the Treatment of Pediatric Severe Asthma

Author(s): Amelia Licari, Riccardo Castagnoli, Enrico Tondina, Giorgia Testa, Giuseppe Fabio Parisi, Alessia Marseglia, Ilaria Brambilla, Gian Luigi Marseglia*.

Journal Name: Current Respiratory Medicine Reviews

Volume 15 , Issue 3 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Estimated to represent less than 5% of all asthmatic patients, children with severe asthma experience troublesome persistent symptoms, life-threatening attacks and side effects by oral corticosteroid treatment, that significantly impact on the quality of life and on economic costs. An accurate understanding of the mechanisms of the disease has been crucial for the discovery and development of biological therapies, for which children with severe asthma are candidates. The aim of this review is to discuss the use of approved biologics for severe asthma, providing updated evidence of novel targeted therapies in the pediatric age range.

Keywords: Benralizumab, children, dupilumab, mepolizumab, omalizumab, reslizumab, severe asthma.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 3
Year: 2019
Page: [195 - 204]
Pages: 10
DOI: 10.2174/1573398X15666190521111816

Article Metrics

PDF: 8

Special-new-year-discount